Hypocholesterolemic Agents II: Inhibition of β-Hydroxy-β-methylglutaryl Coenzyme A Reductase by Arylalkyl Hydrogen Succinates and Glutarates

Synthesis of Alkylarylcarbinols via the Reaction of Organoboranes with Arylmethyl Chlorides

“…1-( p- Chlorophenyl)-1-pentanol (3i). 1 H NMR (CDCl 3 / TMS): δ 7.29 (d, 2H, J = 8.5 Hz), 7.23 (d, 2H, J = 8.5 Hz), 4.58 (t, 1H, J = 6.6 Hz), 2.41−2.10 (br s, 1H), 1.83−1.54 (m, 2H), 1.43−1.14 (m, 4H), 0.87 (t, 3H, J = 6.9 Hz). 13 C NMR (CDCl 3 ): δ 143.3, 133.0, 128.4, 127.2, 73.9, 38.8, 27.8, 22.5, 13.9 ppm.…”

A Review on Synthesis and Applications of Statin Family Drugs as a New Generations of Anti-Blood Medicines

“…In teriperanol, it only prevents the synthesis of cholesterol in the body from the very last stage; however, still desmestrol, which results in blurred vision in the eyes, is produced as biosynthesis. In spite of the findings of the trial of Teri peranol, the search for cholesterol biosynthesis inhibitors continued and hoped that pre-scleral inhibition would prevent intramammary intermediates, such as risperol, and an outcome for the treatment of hypoclostolemia [25]. The enzyme is located in an endoplasmic reticulum membrane and catalyzed (S) -3-hydroxy-3methylglutaryl coenzyme A into 3-(R) -malonic acid via a Hemi-thio acetal in a two-stage conversion (Scheme 4).…”

Foundations for blockbuster drugs in federally sponsored research

“…Often, inhibitors are molecules very similar to the natural substrate(s) of an enzyme, but ones the enzyme cannot convert into a product; the penicillins are examples of such inhibitors. Beginning in the early 1970s, a number of inhibitors were found, but few were potent or specific or could be administered to animals and induce a reduction in cholesterol levels (8,9).…”